Skip to content

To compare the two treatment outcomes for gum bone defects using antibiotic fibers with blood platelet concentrate alone and their healing outcomes

Clinical and radiographic Evaluation of the Efficacy of Local Tetracycline-Loaded Biodegradable Fibers and Platelet Rich fibrin in the treatment of periodontal intrabony defects: A Randomized Controlled Trial. - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/108522
Enrollment
40
Registered
2026-04-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Tetracycline loaded biodegradable fibres with Platelet Rich Fibrin (PRF): Local delivery of tetracycline loaded biodegradable fibres placed into periodontal intrabony defects following

Sponsors

Dr Janani N
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients aged 20 35 years (both males and females) who consented to participate 2)Systemically healthy individuals Diagnosed with Stage II and Stage III periodontitis (Excluding teeth with furcation involvement and mobility) 3)Presence of vertical bone loss of 3 4 mm on radiographic examination 4)Two-wall or three-wall intrabony defects with: Defect depth more 3 mm (confirmed radiographically and intraoperatively) 5)Clinical attachment loss (CAL): 3 6 mm 6)Patients available for regular follow-up visits 7)Patients who provided signed informed consent

Exclusion criteria

Exclusion criteria: 1)Smokers 2)Known allergy or hypersensitivity to Tetracycline groups 3)Patients with uncontrolled systemic diseases (e.g., diabetes, hypertension) that could affect periodontal treatment outcomes. 4)Patients with blood-borne diseases (e.g., HIV, hepatitis). 5)Medications Affecting Blood Clotting:- Patients taking medications that could affect blood clotting (e.g., anticoagulants, antiplatelet agents). 6)Patients with previous history of undergoing flap surgery 7)Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
To compare the radiographic bone fill in intrabony defects treated with tetracycline-loaded biodegradable fibers with PRF and PRF alone, measured by standardized radiovisiography (Fractal Dimensional Analysis) over a defined follow up period of baseline, 1 month, 3 monthTimepoint: To compare the radiographic bone fill in intrabony defects treated with tetracycline-loaded biodegradable fibers with PRF and PRF alone, measured by standardized radiovisiography (Fractal Dimensional Analysis) over a defined follow up period of baseline, 1 month, 3 month

Secondary

MeasureTime frame
To compare the radiographic bone fill in intrabony defects treated with tetracycline-loaded biodegradable fibers with PRF and PRF alone, measured by standardized radiovisiography (Fractal Dimensional Analysis) over a defined follow up periodTimepoint: baseline, 1 month, 3 months; To assess the reduction in probing pocket depth (PPD) in intrabony defects treated with tetracycline-loaded biodegradable fibers with PRF and PRF alone over a follow up period of baseline, 1 month, 3 months. To evaluate the gain in clinical attachment level (CAL) following treatment with both modalities over a follow up period of baseline, 1month, 3 months. To compare changes in Plaque Index (PI) after therapy among both groups over a follow up period of baseline, 1month, 3 months. To compare changes in Gingival Index (GI) after therapy among both groups over a period of baseline, 1 month, 3 months. To compare changes in the Healing Index after therapy among both groups over a period of baseline & 3 months. To evaluate Complete blood count in experimental groups in baseline and 3 months. Timepoint: baseline, 1 months, 3 months

Countries

India

Contacts

Public ContactDr Janani N

Sri Venkateshwaraa Dental College

thirumalai.ney84@gmail.com9894361194

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026